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Contagious bovine pleuropneumonia (CBPP) and contagious caprine pleuropneumonia (CCPP) are major infectious diseases of
ruminants caused by mycoplasmas in Africa and Asia. In contrast with the limited pathology in the respiratory tract of humans
infected with mycoplasmas, CBPP and CCPP are devastating diseases associated with high morbidity and mortality. Beyond their
obvious impact on animal health, CBPP and CCPP negatively impact the livelihood and wellbeing of a substantial proportion of
livestock-dependent people affecting their culture, economy, trade and nutrition. The causative agents of CBPP and CCPP are
Mycoplasma mycoides subspecies mycoides and Mycoplasma capricolum subspecies capripneumoniae, respectively, which have been
eradicated in most of the developed world. The current vaccines used for disease control consist of a live attenuated CBPP vaccine
and a bacterin vaccine for CCPP, which were developed in the 1960s and 1980s, respectively. Both of these vaccines have many
limitations, so better vaccines are urgently needed to improve disease control. In this article the research community prioritized
biomedical research needs related to challenge models, rational vaccine design and protective immune responses. Therefore, we
scrutinized the current vaccines as well as the challenge-, pathogenicity- and immunity models. We highlight research gaps and
provide recommendations towards developing safer and more efficacious vaccines against CBPP and CCPP.
npj Vaccines            (2020) 5:66 ; https://doi.org/10.1038/s41541-020-00214-2
INTRODUCTION
Contagious bovine pleuropneumonia (CBPP) and contagious
caprine pleuropneumonia (CCPP) are important transboundary
diseases of cattle and goats especially in low and middle-income
countries. Both diseases have multiple impacts. Pleuropneumonia
is a very painful clinical state that is associated with reduced
productivity, and, in its most dramatic outcome, death. Death
rates are much higher for CCPP than for CBPP, however, increased
mortality rates are associated with CBPP when infected cattle are
introduced into naive herds1. The adverse affects on productivity
include a reduction in milk production, daily weight gain, draft
power, and fertility among others. Several surveys have ranked
CBPP and CCPP constantly among the top five ruminant diseases
for stakeholders across a range of livestock industry sectors. CBPP
and CCPP are diseases that require precise diagnostic procedures
in order to be detected. The current World Organization for
Animal Health (OIE) prescribed diagnostic tests (cELISA, CFT) are
fit-for-purpose at the herd level but are far from being optimal at
the individual level. Given the passive surveillance approaches,
limited resources, and limited diagnostic capacity in many parts of
Africa and Asia, the current prevalence figures are probably an
underestimate. Nevertheless, prevalence data retrieved from the
OIE specific WAHID interface (Fig. 1 and Supplementary Figure)
over the last 10 years suggests that there has not been any
progress towards control of CBPP and CCPP, especially on the
African continent. Control methods such as movement restric-
tions, quarantine, antibiotic treatment, and vaccination have
had varying success. Reasons for failure to control the diseases
are diverse covering social, economic, and political issues.
Vaccination-related control strategies have been hampered by
variable safety and efficacy of the vaccines and there is an urgent
need for an improved vaccine for both diseases. New vaccines for
these diseases must not only be safe and efficacious, but also cost-
effective, scaleable and accessible to smallholder farmers and this
should underpin rational vaccine design. Scientists from the
research community reviewed the current knowledge on CBPP
and CCPP as well as other mycoplasma discovery research projects
to identify research gaps and agree recommendations at a
workshop in Switzerland (Supplementary Notes). While control
and eradication of these diseases would benefit from new,
improved vaccines, there are many other social, economic and
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political research aspects that need to be addressed, but our focus
in this article is the search for new and better vaccines.
HISTORY OF CONTAGIOUS BOVINE PLEUROPNEUMONIA AND
CONTAGIOUS CAPRINE PLEUROPNEUMONIA AND VACCINES
USED FOR THEIR CONTROL
The timing of the first report on an infectious disease is always
difficult to verify in the absence of good diagnostic tools and
modern high-speed communications that inform and shape
our lives today. CBPP and CCPP were described in the relatively
recent past with astonishingly precise descriptions of the clinical
manifestations. The first records that mention CBPP originate from
Bourgelat in France in 17652, and then more notably from
Albrecht von Haller in Switzerland in 17733. Trade of animals
from Europe to former colonies in ships, facilitated the entry of
CBPP into the southern African continent in 18534, then into
Australia in 1858 and into North America in 1871. The causative
agent, Mycoplasma mycoides subsp. mycoides, was the first
mycoplasma ever cultivated in 18985. These historical accounts
have been confirmed and extended by recent molecular studies
based on genomic data6, showing the existence of at least two
independently imported lineages circulating in Africa6. After
introduction and dispersal of CBPP, the disease was curbed by
either detection and slaughter, combined with movement
restriction (mainly executed by veterinary forces during the
colonial period before 1960), or by the use of a combined live
vaccine against Rinderpest virus and CBPP during the rinderpest
eradication campaign7.
The first report of CCPP dates back to Algeria in 18738.
Subsequently, the disease spread to different countries in Europe,
Asia, and Africa. For instance, a major outbreak struck South Africa
after goats were imported from Turkey in 18819. The fastidious
mycoplasma that causes CCPP, namely Mycoplasma capricolum
subsp. capripneumoniae, was only identified in 197610. More
recently, the Thrace region of Turkey experienced a CCPP outbreak
with high mortality in 200211 and the disease now seems to be
endemic there12.
There are two vaccines being produced and used in the field for
CBPP and CCPP. If manufactured and applied properly they have
the capacity to prevent clinical disease and economic loss13,14.
Interestingly, the CBPP vaccine is a live attenuated vaccine, while
the CCPP vaccine is a bacterin.
The CBPP vaccine was attenuated by serial cultivation in eggs in
the 1950’s and is based on the Tanzanian outbreak strain T1, with
the 44th passage (T1/44) used as vaccine stock. The vaccine
provides a level of protection that can be quantified by reduction
in lung lesions in vaccinated and challenged cattle compared to
unvaccinated and challenged animals. As it is a live vaccine, it can
theoretically be combined with other live vaccines, an approach
that was used successfully during the Rinderpest eradication
campaign. This live bivalent vaccine containing streptomycin led
to a marked reduction in CBPP in Rinderpest-affected countries15.
Annual revaccination with the live vaccine is necessary to maintain
protective immunity. It is relatively inexpensive and easy to
produce at scale, as the cultivation of M. mycoides subsp. mycoides
is much easier than cultivation of many other pathogenic
Mycoplasma species, such as M. hyopneumoniae (the primary
agent of enzootic pneumonia in pigs), M. capricolum subsp.
capripneumoniae or M. pneumoniae (the cause of atypical
pneumonia in humans). A minimal vaccine dose of 107 colony-
forming units of M. mycoides subsp. mycoides is recommended by
OIE, so many doses can theoretically be achieved during
commercial production from 1ml of culture (which typically
contains 109 CFU/mL). In some instances, severe inflammation at
the site of inoculation has been caused from this vaccine,
especially after primary vaccination of cattle. This so-called
Willems reaction is characterized by massive inflammatory
reactions that can lead to skin sloughing at the vaccination site
and in the worst case to death. Therefore, in the 1960s, Australian
cattle were immunized at the tip of the tail with the V5 live
vaccine, so that in the event of severe reactions the only effect
was the loss of the tip of the tail. These reactions have an adverse
effect on owner acceptance, and on animal welfare and market-
ing, leading to a low uptake of this vaccine. Anecdotal data
suggest breed predispositions to these side effects. In addition, it
has been shown that the T1/44 live vaccine strain is not fully
attenuated and can cause disease when inoculated endobronchi-
ally16. Mass vaccination even with a moderate efficacy and
duration of immunity vaccine (such as the current T1/44 live
vaccine) alone is unlikely to eliminate CBPP according to an
epidemiological model for CBPP transmission in pastoral herds of
East Africa17,18. This includes a requirement for strict movement
controls and the authors say it is validated by field observation.
Furthermore, vaccine-derived immunity of at least 18 months is
required to eliminate CBPP from individual herds according to
recent study13. A combination of vaccination and antibiotic
Fig. 1 Occurrence of contagious bovine pleuropneumonia (CBPP) and contagious caprine pleuropneumonia (CCPP) from 2010 to 2019.
Countries displayed in orange, purple, and turquoise reported confirmed cases of CBPP, CCPP, or both CBPP & CCPP, respectively. Data were
collected from the website of the World Organization of Animal Health (www.oie.int).
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treatment of diseased cattle turned out to be most promising for
CBPP control according to the epidemiological model18.
The current CCPP vaccine is a bacterin, and the OIE provides the
guidelines for its production, which is basically culturing any field
isolate and inactivating with saponin, which acts as an adjuvant.
This vaccine was developed in the 1980s and 1990s19,20. The
vaccine is administered as early as 4 months of age and
revaccination is recommended every 6 months. The production
of this vaccine is rather cumbersome given the fastidious growth
requirements of the pathogen. Moreover, the vaccine dose of
150 µg total protein is relatively high, making the vaccine
expensive compared to other caprine vaccines. The OIE protocol
recommends 3mg of the adjuvant saponin per vaccine dose,
which exceeds standard saponin concentrations (0.3 mg per dose)
for small ruminants. The main drawback of this otherwise safe
vaccine is the inflammatory reactions at the site of vaccination21,
possibly due to the saponin adjuvant, and the short duration of
immunity of only 6 months to maximally 1 year. These limitations
might be overcome with new adjuvant formulations. Given the
envisaged eradication of Peste des Petits Ruminants (PPR), a live
CCPP vaccine that can be combined with the PPRV vaccine and
other live vaccines would be desirable. Such a vaccine would save
cost in terms of production and logistics associated with vaccine
delivery. Given the widespread use of the live T1/44-based CBPP
vaccine despite its residual pathogenicity16, live strains of M.
capricolum subsp. capripneumoniae, which can be safely injected
subcutaneously, should be tested for their ability to induce a
protective immune response.
The limitations of the current CBPP and CCPP vaccines have led
to a search for better vaccines. A lapinized vaccine based on the
passaged strain Ben-1 has been used during the eradication of
CBPP in China in the framework of a comprehensive eradication
program22. This vaccine is reported to provide 95–100% protec-
tion over 2 years, which is superior to other mycoplasma vaccines
and most commercial ruminant vaccines. However the method
used for its production, intraperitoneal inoculation of sheep, is
unacceptable under current animal welfare standards.
An experimental vaccine batch based on the lapinized strain but
produced in culture media was compared with the commercial T1/
44 vaccine in an in vivo trial on African cattle breeds, but its
protective capacity was not superior to the commercial T1/44
(https://www.galvmed.org/galvmedat10/05-key-achievements.html).
One of the key learnings of eradication of CBPP in China is that the
lapinized and its sheep-adapted vaccine were paramount for the
establishment of immunity zones around enzootic regions besides
the other undoubtedly important control measures such as move-
ment control as well as detection and slaughter.
Recently, using a reverse vaccinology approach researchers
identified several candidate vaccine antigens that conferred
protective immune responses to experimental CBPP challenge23.
Further work has been ongoing to optimize the vaccine (scale up,
duration of immunity, field testing, and comparison with T1/44
vaccine) with commercial acceptance in mind.
Any new vaccine should be tested under different field conditions
and different control strategies identified using epidemiological
models and previous local experience if available, to guide and
inform national and regional control policy makers. An additional
consideration is the uptake of livestock vaccines by smallholder
farmers and marginalized populations which may require different
strategies depending on factors such as the type of disease to be
tackled, the value of the livestock species, the market size,
profitability as well as the support of national and regional vaccine
manufacturers among others. Vaccine adoption is influenced by
availability of, access to and demand for vaccines. Global and
national vaccine campaigns differ from market-driven approaches.
The different strategies to increase adoption of animal vaccines by
smallholder farmers especially in low and middle-income countries
have been very capably reviewed recently24 and, as mentioned for
implementation of control strategies, will not be further discussed.
VIRULENCE TRAITS, PATHOGENICITY MODELS, AND
POTENTIAL VACCINE TARGETS FOR CBPP AND CCPP
Most work on deciphering the factors that drive pathogenicity in
these two pathogens has been performed on CBPP, probably
because of European outbreaks in the 1980s and 1990s, which
subsequently attracted research funding to several European
laboratories. It has been proposed that African and European
strains differ in virulence, this was based on an in vivo in-contact
challenge study employing 2 groups of 2 animals each, which
were infected with different M. mycoides subsp. mycoides strains.
Strictly speaking only 3 animals were used, since one animals
stayed seronegative after the first in-contact challenge and was
subsequently reused in the other challenge group. Clinical signs of
all 4 in-contact animals were very mild (nasal discharge) and
pathomorphological changes were not seen in any of these in-
contact challenged animals irrespective of the strain used25. The
only difference observed was an earlier onset of seroconversion in
animals in-contact with a donor infected with the African strain
Afadé26. Later on it was shown by others that experimentally
infected cattle developed different seroconversion profiles,
described as early high responders, late high responders, and
low responders27.
The African and European strains differed in a genetic locus
encoding the ATP-binding cassette transporter proteins GtsA,
GtsB, and GtsC, which were proposed to be involved in glycerol
transport. The European strains missing this locus produced lower
concentrations of H2O2
28. Based on the association between this
metabolic difference and the late seroconversion after infection
with the European strain L2, it was concluded that H2O2
production is a virulence trait. A mycoplasma metabolic enzyme
called glycerol phosphate oxidase (GlpO) was identified as central
in the production of peroxide in the presence of physiological
glycerol29. This mechanism has been proposed as the main
virulence mechanism of CBPP30 without confirmation using
ex vivo or in vivo data according to Falkow’s postulates31. More
recently, immunization experiments using recombinant GlpO
followed by challenge did not demonstrate protection, which
may be because either H2O2 production is not a main virulence
trait or that GlpO itself is mainly cytoplasmic32, preventing
antibodies from inhibiting its function.
Several other virulence traits have been suggested, but mainly
based on in vitro systems with little or no data available from
ex vivo or in vivo models. Since successful challenge of cattle with
M. mycoides subsp. mycoides is difficult (see below) and efficient
genetic tools to produce isogenic mutants are unavailable33,
researchers have focussed instead on the caprine pathogen M.
mycoides subsp. capri, in order to decipher virulence traits in
Mycoplasma mycoides and test them in vivo. These studies have
used synthetic genomics techniques, which allow unprecedented
precise genome engineering of mycoplasmas34–39 and a caprine
challenge model40–42. These experiments have provided in vivo
evidence that capsular polysaccharide is a virulence trait in
Mycoplasma mycoides40, as suggested more than 40 years ago43.
They also have enabled the generation of a temperature-sensitive
mutant of M. mycoides subsp. capri by targeting the essential gene
obg42. However, this mutant did not seem to induce a strong
protective immune response against a challenge with the wild
type strain.
Another candidate virulence factor is the MIB-MIP system that is
proposed to degrade immunoglobulins44. It is not difficult to
imagine an extracellular pathogen (the current understanding of
the habitat of these pathogens) would be shielded by interference
with the function of host immunoglobulins, thus contributing to
J. Jores et al.
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survival and pathogenicity. The in vitro proteolytic activity of the
system has recently been confirmed in vivo41.
Last but not least, lipoproteins and variable surface proteins are
candidate virulence factors that definitely deserve more research45.
Like the capsular polysaccharide and the MIB-MIP system these
cellular components are located on the pathogen’s surface and are
therefore the primary molecules interacting with the host. It is
known that for certain Mycoplasma species particular lipoproteins
act as variable surface antigens [for review see:46] and facilitate
evasion of the host’s immune response. Some of the lipoproteins
show some degree of amino acid sequence identity across different
Mycoplasma species, but their exact role in virulence has not been
deciphered for M. mycoides subsp. mycoides and M. capricolum
subsp. capripneumoniae. It has been suggested that they contribute
to an overwhelming immune response that leads to immunopatho-
logical consequences47. The lipid moieties of Mycoplasma pneumo-
niae lipoproteins have been recently suggested as causative factor
of vaccine-enhanced disease using a mouse model48.
RESEARCH GAPS TO BE ADDRESSED
For clarity and a more systematic approach we have subdivided
this important area into three topics. We summarized the current
state of research blocks (Fig. 2) and a priority list of recommended
research needs (Table 1).
Challenge models
A reproducible challenge model is a conditio sine qua non for the
development of a vaccine. Most mycoplasmas includingM. mycoides
subsp.mycoides and M. capricolum subsp. capripneumoniae are host-
target tissue specific. We should focus on the natural host and
improve, if needed, the available challenge models. But which
challenge models are available? For CCPP, of late a novel challenge
model has recently been reported49, based on the recent Kenyan
outbreak strain ILRI18150. This model is based on a combination of
two subsequent inoculations of aerosols of cultures into the nasal
cavity of goats followed by a trans-tracheal inoculation. Morbidity of
100% and a mortality of 50–60% was seen in infected animals,
closely mimicking natural infection49. Improvements of the chal-
lenge model are possible, including titration of the challenge dose,
use of an aerosol chamber for infection as has been used for
experimental infections with other Mycoplasma species51,52, and
whether either the aerosol or the trans-tracheal inoculations are
dispensable to allow simplification of the procedure. However, given
the robustness of the model thus far and its potential to be
implemented in resource-poor settings, improvement of the model
is currently a lower priority (Fig. 2). We encourage the development
and employment of caprine airway epithelial cell cultures such as
used in the human Mycoplasma field53–56.
The current challenge models for CBPP are less advanced and
are suboptimal, as they have resulted in a variety of outcomes
ranging from no clinical disease26 to a wide spectrum of
pathological lesions23,47,57–59. A common feature of these models
is the intratracheal inoculation of a Mycoplasma culture using a
tube that is inserted via the nasal or oral cavity while the animal is
standing or in lateral recumbency. In the past, fresh cultures were
used for inoculation, however, it has now been demonstrated that
frozen stock cultures work well for both pathogens60,49. The
instillation of a solution of agar after inoculation of the
mycoplasma broth culture has been show to be dispensable60.
Trans-tracheal inoculation is easy to perform in Bos taurus cattle
but is difficult in Bos indicus animals, as the dewlap in these
animals impedes access and a Willems reaction is likely to occur.
Given the range of disease severity with intratracheal inoculation
reported so far, systematic development of a robust and
reproducible challenge model for CBPP is clearly a priority
(Fig. 1, Table 1). It needs to be based on a low passage field
isolate, using cattle over 1 year of age and a defined dose of the
organism. A good option would be to try aerosolized cultures and
repeated inoculations, as this best mimics the natural route of
infection. As a starting point, results obtained with M. bovis using
an aerosol chamber to induce experimental infection in calves
should provide some guidelines for further development51. A
standardized challenge model, preferably using a single aliquoted
frozen challenge stock, would allow data to be exchanged and
compared more easily, a critical requirement given the high costs
and logistical challenges associated with large animal trials. This
way, the research community could benefit the most from data
generated in in vivo trials, which generally trump data derived
from in vitro and ex vivo assays.
In-contact infection models were not considered a practicable
alternative as the timing of individual infection and disease signs
are difficult to synchronize because of differences of interactions
between animals, which influence transmission of disease. There-
fore, such models are intrinsically more variable, require a large
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Fig. 2 Cartoon displaying the major research blocks that influence rational vaccine design. The characteristics of the current CBPP and
CCPP vaccines are displayed on the left. The state of knowledge is characterized by traffic lights (red—missing; yellow—partly available; green
—available).
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number of animals and are not the best option for the read out of
immunological parameters over time. Moreover, recently estab-
lished ex vivo models61,62 for deciphering pathogenicity mechan-
isms and identifying virulence traits may prove beneficial (Table 1).
CANDIDATE VACCINE ANTIGENS AND ATTENUATION TARGETS -
FILLING THE KNOWLEDGE GAP ON MYCOPLASMA
Mycoplasmas lack a cell wall and due to their inherent minute size
one might assume that they are easily characterized, but this is
not the case. In fact, we know relatively little about the structure
and physiology of M. mycoides subsp. mycoides and M. capricolum
subsp. capripneumoniae. This is influenced by the classification as
BSL3 pathogens in some countries, restricting many research
laboratories from working with them, and by the lack of genetic
tools to induce defined mutations. However, the advent of
synthetic genomics has paved the way for mutagenesis of a
closely related subspecies of M. mycoides subsp. mycoides namely
M. mycoides subsp. capri35–38. The availability of diverse next
generation sequencing platforms has enabled researchers to
characterize the genomes of M. mycoides subsp. mycoides63 and M.
capricolum subsp. capripneumoniae50,64, demonstrating relatively
little sequence diversity6,65.
What we lack at present is characterization of the pan and core
genome of M. mycoides subsp. mycoides, M. capricolum subsp.
capripneumoniae and the entire “M. mycoides cluster”. This
information is likely to help us identify common genes among
mycoplasmas that play a role in fitness and persistence in hosts
and to identify new vaccine targets or sites for attenuation. A
detailed transcriptomics analysis, preferably combined with
proteomics studies is also missing. This would provide baseline
data that could be used to tease apart operons and promoters and
enable us to better understand the organisms’ physiological
pathways as well as improve the annotation of the genomes for
the sake of rationale vaccine design.
The mycoplasma metabolism depends on scavenging a wide
range of host molecules, as mycoplasmas are unable to synthesize
many of the precursors for their macromolecules (including
proteins, nucleic acids, and lipids). This scavenging lifestyle requires
transporters that span the cell membrane and translocate the
scavenged molecules to the enzymatic apparatus inside the
mycoplasma cell. Interference with such transporters is likely to
affect the growth and viability of mycoplasmas substantially, so
essential transporters are likely to be promising targets in future
rationale vaccine efforts. Candidates have already been identified
in other Mycoplasma species that are present in the “Mycoplasma
mycoides cluster”, including the putative oligopeptide/dipeptide
(opp/dpp) ATP-binding cassette (ABC) transporter66,67. Therefore, a
combination of in silico analysis and OMICS data (proteomics,
transcriptomics, metabolomics) is likely to enable us to identify
transporters that should be target for future characterization.
However, we need to know more about lipoproteins and other
surface-exposed proteins of these mycoplasmas, and particulary
their function and abundance in order to identify protective
antigens to be tested later on (Table 1). The core in vitro surface
proteome of M. mycoides subsp. mycoides has been suggested to
include about 50 lipoproteins and other membrane proteins68.
Some of these have been shown to be immunogenic69 and even
to induce a protective immune response23, while others have been
suggested to contribute to immunopathology47. Understanding of
the surface proteome of M. capricolum subsp. capripneumoniae is
lagging behind. Many genes encoding putative lipoproteins and
transmembrane proteins have been identified in silico50,64,70, but
data regarding their expression, function and immunogenicity are
lacking. It will be important to first confirm the cellular localization
of these proteins in M. mycoides and M. capricolum using either
available fluorescent molecules (e.g., mCherry, mNeon)71 or tags
coupled with electron microscopy among others. This work would
allow the research community to build a list of surface-exposed
virulence candidates that can be further tested in ex vivo and
in vivo systems discussed above. In an effort to initiate such a
process, we have listed the candidate virulence traits that we
believe require immediate attention (Table 2).
Some of the mycoplasma lipoproteins identified so far can be
classified into different families, as they possess conserved
domains of unknown functions (DUFs). Some of these families
are found throughout the phylum Firmicutes (which includes the
class Mollicutes) while others appear to be “mycoplasma-
specific”. Functional studies of these proteins are not trivial as
functional redundancy is likely to occur between the different
family members. Until efficient genetic tools are available for M.
mycoides subsp. mycoides and M. capricolum subsp. capripneu-
moniae, we suggest using the closely related pathogens M.
mycoides subsp. capri and M. capricolum subsp. capricolum,
respectively, as a model to characterize these lipoproteins (Fig.
2). The capacity to delete multiple genes or even subgenomic
fragments in the genomes of M. mycoides subsp. capri and M.
capricolum subsp. capricolum will allow the generation of strains
in which all members of a DUF family have been removed. Using
such a mutagenesis system, five genomic regions of M. mycoides
subsp. capri strain GM12 comprising 68 genes were deleted
recently41. In addition to the glycerol metabolism-related genes,
the deleted genes encoded 18 lipoproteins and 21 transmem-
brane proteins. This resulted in the complete attenuation of this
otherwise pathogenic strain. The same synthetic genomics tools
have been used to graft heterologous subgenomic Mycoplasma
Table 1. Five top research priorities for the development of CBPP and CCPP vaccines.
Priority Contagious Bovine Pleuropneumonia Contagious Caprine Pleuropneumonia
1 Development of a robust challenge model Characterization of surface-localized virulence factors
2 Ex vivo and in vivo verification of surface-localized virulence factors
using harmonized caprine models and M. mycoides subsp. capri (see
Table 2)
Generate mutants and confirm attenuation in harmonized caprine
ex vivo models
3 Generate M. mycoides subsp. mycoides mutants based on mutations
that led to attenuation in an M. mycoides subsp. capri model (see
priority 2) and test them as a live vaccine in vivo
Test candidate mutants for attenuation and induction of immune
responses in vivo
4 Extend and revisit immunological knowledge based on correlates of
protection using the novel challenge model (see Priority 1):
characterize the innate and adaptive immune responses (local and
systemic) after infection of vaccinated and naïve animals
Define immunological correlates of protection: (1) perform adoptive
transfer of caprine IgG harvested from immune animals following
immunization & challenge; (2) characterize the innate and adaptive
immune responses (local and systemic) after infection of vaccinated
and naïve animals
5 Characterize the Willems reaction and the mycoplasma factors that
drive it
Applying systems immunology to improve the adjuvant formulation
used for the current bacterin vaccine
J. Jores et al.
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fragments into M. mycoides subsp. capri (unpublished data),
generating a useful tool for future characterization of a subset of
M. mycoides subsp. mycoides and M. capricolum subsp. caprip-
neumoniae target molecules.
Another interesting feature of mycoplasmas is their exosecre-
tion of bacterial compounds that can interact with their hosts. M.
mycoides cell membranes have been shown to have several
protrusions that can themselves have several constrictions63.
Extracellular vesicles have also been shown to be released by
mycoplasmas72. Other mycoplasmas, including M. hyopneumo-
niae, shed extracellular domains of proteins73 and this has also
been observed for M. capricolum subsp. capripneumoniae and M.
mycoides subsp. mycoides74. The role of these secreted vesicles
and proteins in the pathogenesis of mycoplasmoses, if any, needs
to be determined in future studies.
In the interest of maximizing the benefit obtained from limited
resources we suggest focusing research activities on a defined set
of mycoplasma strains in order to generate synergies and facilitate
comparisons between in vivo, ex vivo, and in vitro data (Table 1).
DEFINING CORRELATES OF IMMUNITY AND CHARACTERIZING
IMMUNE RESPONSES AFTER INFECTION
Most of the immunological data generated this far has been
collected by the research groups at CIRAD, the International Livestock
Research Institute and the Kenya Agricultural & Livestock Research
Organization, who have been undertaking vaccine development
work. In the interest of time and space we do not include in vivo data
that have been collected from rodent models, which are not likely to
be as informative about protective immune responses in domestic
ruminants. In their natural hosts, immunizations with a live CBPP
vaccine or a CCPP bacterin induce a protective immune response.
This immunity needs to be dissected to foster rational design of
improved vaccines (Table 1).
We suggest performing adoptive transfer experiments with
purified antibodies from convalescent, diseased, and healthy
animals to animals that are subsequently infected experimentally.
Such activities should be initiated with CCPP, as the infection
model is well established, and large amounts of sera have been
collected from convalescent animals at necropsy during a recent
trial49. If the adoptively transferred antibodies are protective, we
can focus on characterization of the spectrum of specificities of
the antibodies using bead-based assays and bioinformatic net-
work analysis of B-cell responses in protected animals. A similar
experiment should be done with CBPP, when a better challenge
model is available.
Traditional methods of determining the protective role of T-cell
mediated immunity, by depleting specific subsets of T cells have
been performed for CBPP57. Such depletion experiments require
large quantities of monoclonal antibodies directed against
markers on ruminant T cells, and often necessitate repeated
administration. Their interpretation can be misleading because
T cells are a component of an interactive system and removing
any one element can have an impact on the whole system.
Furthermore, many cell surface markers are not unique to one
population. Therefore, alternative approaches may be useful, such
as those arising from the field of systems immunology75 and
systems vaccinology76, which have recently been adapted from
humans to livestock species77,78. High-throughput technologies
such as RNA sequencing coupled with data analysis allow the
interrogation of hosts’ intracellular and intercellular interactions to
understand the entire immune system better. It permits explora-
tion of mechanistic insights, which enables vaccines to induce
protective immune responses. The principle of such analyses is the
collection of very large data sets by examining responses of
immune cells using advanced immunological techniques and
transcriptomic analyses. Changes in the transcriptional modules
and changes in the immune responses can be analysed for any
correlations to identify elements of the innate and adaptive
immune response that promote protection in ruminants. It can be
used to analyse both live and inactivated vaccine responses and
correlate them with protection and to identify a suitable adjuvant
that promotes longlasting immunity76. Applying such technolo-
gies to the current bacterin CCPP vaccine and novel CBPP and
CCPP vaccine candidates will inform on the mechanism of
protection, including both antibody responses and responses
by different types of T cells, including the role of T helper (Th)1,
Th2, and Th17 or regulatory T cells (Table 1). Although these
approaches are resource intensive and require bioinformatic and
immunological expertise, they will enable a more rational design
of vaccine and accelerate the development of improved vaccines.
Future research focusing on components of mucosal immunity
such as secretory IgA levels that can prevent infection is also
required, as it is known with other mycoplasma vaccines that
systemic antibody does not necessarily correlate with protection
against lung pathology79.
The characterization of the innate immune response is also
paramount, as the innate immune response is likely to determine
the outcome of infection or immunization by directing the type of
adaptive immune response that ensues, and is also the first line of
defence against the pathogen. It is self-evident that granulocytes80
and macrophages81 infiltrating the site of infection shape the
outcome of disease and the pathogenicity. Therefore, their
interaction with the pathogen and its components needs to be
closely followed to generate a more complete picture of the
mechanisms underlying the development of lesions initiated by
either the pathogen or the host immune response. New and
improved adjuvants and immune modulators are available that can
increase the duration of immunity and direct the immune response
towards more protective responses. These should be evaluated,
Table 2. Prioritization of candidate virulence factors for investigation according to Falkow’s postulates.
Priority Candidate virulence factor Comment
1 L-alpha-glycerophosphate oxidase (GlpO) Knock out mutants are available for M. mycoides subsp. capri, the role of this
candidate virulence factor requires immediate investigation, as it is dispensable for
virulence in M. gallisepticum
2 MIB-MIP system Knock out mutants are already available for M. mycoides subsp. capri, in vivo activity
has been proven and this is a top candidate virulence factor
3 Different DUF groups of lipoproteins Individual lipoproteins and pathogen specific DUF groups of lipoproteins need to be
tested for their role in virulence
4 Variable surface proteins Have been shown in vitro and in vivo to be functional in mycoplasmas
5 Oligopeptide/dipeptide (opp/dpp) ATP-binding
cassette (ABC) transporter
Has been shown in M. agalactiae to be a candidate virulence factor
6 6-phospho-beta-glucosidase (Bgl) Correlations indicate a role in cytotoxicity
J. Jores et al.
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using the data generated in the experiments described above to
guide selection of the most appropriate candidate vaccines.
PRIORITIZATION OF RESEARCH EFFORTS TOWARDS A NOVEL
PROPHYLACTIC VACCINE
Prioritization largely depends on the point of view of individual
researchers, with microbiologists favouring characterization of the
pathogen and immunologists favouring the characterization of
the immune responses. However, a closer interaction between
these two groups is needed to best tackle pathogens that kill our
livestock in such large numbers. After rigorous scientific discus-
sions, our suggested priority actions are shown in Table 1. We
believe these approaches will guide development of better
vaccines that can be used as tools in the control of these two
important pathogens.
However, even the most efficacious vaccine does not alone
imply its adoption and successful disease control. The Rinderpest
eradication taught us that any vaccination campaign needs to
involve many stakeholders such as epidemiologists and social
scientists to develop and implement policies and strategies to
achieve successful disease control7.
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